Isavuconazole use and TDM in real-world pediatric practice-Reference-Cited by-同舟云学术

Isavuconazole use and TDM in real-world pediatric practice

Published:2023-12-14 Issue:12 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Fernández Ledesma Berta¹^ORCID,Mendoza-Palomar Natalia¹^ORCID,Melendo Pérez Susana¹,Fernández-Polo Aurora²,Renedo Miró Berta²,Pau Parra Alba²,Luque Pardos Sonia³,Grau Cerrato Santiago³,Vima Bofarull Jaume⁴,Martín-Gómez María Teresa⁵,Pujol Jover Montserrat⁶,Benítez-Carbante Maria Isabel⁷,Díaz de Heredia Cristina⁷,Soler-Palacin Pere⁸

Affiliation:

1. Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Infantil. Vall d’Hebron Barcelona Hospital Campus, Institut de Recerca Vall d’Hebron, Barcelona, Catalonia, Spain

2. Pharmacy Department, Hospital Infantil, Vall d’Hebron Barcelona Hospital Campus, Institut de Recerca Vall d’Hebron, Barcelona, Catalonia, Spain

3. Pharmacy Department, Hospital del Mar, Barcelona, Catalonia, Spain

4. Department of Clinical Biochemistry, Central Clinical Laboratories, Vall d’Hebron Barcelona Hospital Campus, Institut de Recerca Vall d’Hebron, Barcelona, Catalonia, Spain

5. Microbiology Department, Vall d’Hebron Barcelona Hospital Campus, Institut de Recerca Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain

6. Pediatric Intensive Care Unit, Hospital Infantil, Vall d’Hebron Barcelona Hospital Campus, Institut de Recerca Vall d’Hebron, Barcelona, Catalonia, Spain

7. Pediatric Oncology and Hematology Department, Hospital Infantil. Vall d’Hebron Barcelona Hospital Campus, Institut de Recerca Vall d’Hebron, Barcelona, Catalonia, Spain

8. Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Infantil. Vall d’Hebron Barcelona Hospital Campus, Institut de Recerca Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain

Abstract

ABSTRACT Isavuconazole (ISA) is approved for treating invasive aspergillosis and mucormycosis in adults, but its use in children remains off-label. We report on the use of ISA in real-world pediatric practice with 15 patients receiving ISA for treatment of invasive fungal infections. Therapeutic drug monitoring (TDM) was performed in all patients, with 52/111 (46.8%) C trough determinations out of range, thus supporting the need for TDM in children, especially those receiving extracorporeal membrane oxygenation (ECMO).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00829-23

Reference27 articles.

1. Invasive mold infections in iatrogenically immunocompromised children: An eight-yr review

2. Pediatric Invasive Aspergillosis: A Multicenter Retrospective Analysis of 139 Contemporary Cases

3. Invasive Fungal Infections in Children

4. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

5. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Invasive Fungal Disease in Immunocompromised Children: Current and Emerging Therapies;Current Infectious Disease Reports;2024-08-31

2. A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole;Medical Mycology;2024-08-13